NEW YORK, August 22, 2016 /PRNewswire/ --
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
Last Friday, South Plainfield, New Jersey headquartered PTC Therapeutics Inc.'s stock fell 1.35%, to close the day at $8.03 with a total volume of 304,155 shares traded. The Company's shares have advanced 10.00% in the last month and 0.37% over the previous three months. The stock is trading 13.90% above its 50-day moving average. Additionally, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have a Relative Strength Index (RSI) of 61.96.
On July 26th, 2016, research firm Wedbush reiterated its 'Neutral' rating on the Company's stock with a decrease of the target price from $12 a share to $10 a share.
On August 4th, 2016, PTC Therapeutics reported total revenues for Q2 2016 of $15.6 million compared to $6.8 million in the same period of 2015. The change in total revenue was a result of the expanded commercial launch of Translarna, but was partially offset by lower grant revenue. The company's net loss for Q2 2016 was $38.9 million compared to a net loss of $38.4 million for the same period in 2015. The free research report on PTCT is available at: http://stock-callers.com/registration/?symbol=PTCT
Shares in Barcelona, Spain headquartered Grifols S.A. finished Friday's session flat at $16.40. The stock recorded a trading volume of 326,863 shares. The Company's shares have gained 11.56% in the previous three months and 2.19% on an YTD basis. The stock is trading above its 200-day moving average by 3.50%. Furthermore, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 45.77. The complimentary report on GRFS can be downloaded at: http://stock-callers.com/registration/?symbol=GRFS
Los Angeles, California headquartered Puma Biotechnology Inc.'s stock finished 1.32% lower at $50.09 last Friday at the close, with a total volume of 313,281 shares traded. The Company's shares have surged 45.10% in the past month and 56.78% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 31.48% and 7.79%, respectively. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have an RSI of 66.11.
On August 9th, 2016, Puma Biotechnology reported a net loss applicable to common stock of $66.6 million, or $2.05 per share, for Q2 2016, compared to a net loss applicable to common stock of $64.7 million, or $2.01 per share, for Q2 2015. At June 30th, 2016, Puma Biotechnology had cash and cash equivalents of $57.8 million and marketable securities of $85.9 million compared to cash and cash equivalents of $31.6 million and marketable securities of $184.3 million at December 31st, 2015. Visit us today and download our complete research report on PBYI for free at: http://stock-callers.com/registration/?symbol=PBYI
22nd Century Group
Shares in Clarence, New York headquartered 22nd Century Group Inc. ended last Friday's session 1.85% higher at $1.10. The stock recorded a trading volume of 671,254 shares, which was above its three months average volume of 507,660 shares. The Company's shares have advanced 36.49% in the last month and 42.75% over the previous three months. The stock is trading 27.06% above its 50-day moving average and 9.05% above its 200-day moving average. Moreover, shares of 22nd Century Group, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 71.59.
On August 9th, 2016, 22nd Century Group reported that net sales revenue for Q2 2016 were $2,828,000, an increase of 22.6% over net sales revenue of $2,307,000 for the three months ended June 30th, 2015. The company's net loss for Q2 2016 was $2,902,000, or ($0.04) per share, as compared to a net loss of $1,289,000, or ($0.02) per share, for the year ago period.
On August 11th, 2016, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $4.50 a share to $3.50 a share. Get free access to your technical report on XXII at: http://stock-callers.com/registration/?symbol=XXII
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA